Project description
Nanovaccines for targeted immunotherapy
Vaccine development has evolved significantly over the years, from traditional methods using inactivated or weakened pathogens to advanced technologies like nanovaccines. With the support of the Marie Skłodowska-Curie Actions programme, the PCPanCel project focuses on creating nanovaccines for more precise, effective and faster responses to cancer. These nanovaccines will incorporate polymer vesicles decorated with immunogenic oligopeptide antigens. By modifying the properties of these vesicles, researchers aim to understand how different immune responses are initiated and to establish the link between nanovaccine structure and immune signalling pathways. Project findings will potentially lead to optimised immunotherapy solutions for cancer.
Objective
Understanding the relationship between the structure of drug formulations and their function is of utmost importance for the prediction of treatment outcome. This has become highly apparent from the recent development of lipid nanoparticle-based vaccines to prevent COVID infections. It has also become clear that many questions remain which require a robust approach to this exciting field of nanomedicine. This project aims at precisely modulating supramolecular nanovaccines, systematically investigating their interaction with immune cells, and finally establishing the relationship between the physicochemical properties and the immune response pathways. The supramolecular nanovaccines will exploit block copolymer vesicles (polymersomes) as scaffolds which will be decorated with immune active (antigenic and adjuvant) oligopeptides on their surface. Such minimized supramolecular vaccine design enables flexibility with regard to physicochemical properties in terms of size, shape and surface character. The interaction of this library of nanovaccines with immune cells will provide a deeper insight in how different immune responses can be provoked. By precisely controlling the physicochemical properties of the nanovaccines, the project will explain cascade signalling pathways on both the cellular- and molecular level, with as final target to aid in vaccine design for especially tumor immunotherapy.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences medical biotechnology nanomedicine
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-MSCA-2022-PF-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
5612 AE Eindhoven
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.